Clinical Study on the Effectiveness and Safety of Guanxinning Tablets on Coronary Heart Disease Complicated with Diabetic Nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100005416

Enrollment

Unknown

Registered

2021-12-17

Start date

2021-12-20

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease combined with diabetic nephropathy

Interventions

test group:Conventional treatment + Guanxinning tablets

control group :Conventional treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of blood stasis syndrome of coronary heart disease ("Diagnostic criteria of blood stasis syndrome of coronary heart disease"); (2) Meet the diagnostic criteria for diabetes (diabetes mellitus, DM) established by the ADA in 2020; (3) Those who meet one of the following conditions ("Chinese Guidelines for Clinical Diagnosis and Treatment of Diabetic Kidney Disease 2021"): ?Random urinary albumin/creatinine ratio (UACR) = = CR or urinary albumin excretion rate (UAER) = = R white excretion rate (( "sugar, and repeat check UACR or UACR within 3-6 months) UAER, 2 out of 3 times reached or exceeded the critical value. ?Estimate the glomerular filtration rate (eGFR) <60ml glomerular filtration rate (. "Sugar 3m-2, more than 3 months. ?Kidney biopsy conforms to the pathological changes of diabetic kidney disease (DKD). (4) Those aged =18 years, =, =years old; (5) Subjects are informed and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Does not meet the inclusion criteria; (2) People with infection, fever, congestive heart failure, uncontrolled blood sugar and blood pressure, or urinary tract infection; (3) Unwilling to cooperate and mentally ill patients; (4) Patients with serious diseases such as heart, lung, brain, liver, kidney, hematopoietic system, etc.; (5) ALT and AST are higher than 3 times the upper limit of the normal range; (6) Patients who have participated in clinical trials of other drugs in the past month; (7) Women who are pregnant or preparing to become pregnant or breast-feeding; (8) Those who have a history of drug allergy or allergic physique and are allergic to multiple drugs; (9) Other patients who do not meet the selection criteria as judged by the investigator.

Design outcomes

Primary

Measure	Time frame
24-hour urine protein quantification;Urine albumin/creatinine ratio;Estimated glomerular filtration rate;	—

Secondary

Measure	Time frame
Changes in inflammation levels;Glycated hemoglobin;Fasting blood glucose;Blood lipids;	—

Countries

china

Contacts

Public ContactXu Zhao

13735527510@163.com13735527510

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026